SETD1A, a Set1/COMPASS family member maintaining histone-H3-lysine-4 (H3K4) methylation on transcriptionally active promoters, is overexpressed in breast cancer. Here, we show that SETD1A supports mitotic processes and consequentially, its knockdown induces senescence. SETD1A, through promoter H3K4 methylation, regulates several genes orchestrating mitosis and DNA-damage responses, and its depletion causes chromosome misalignment and segregation defects. Cell cycle arrest in SETD1A knockdown senescent cells is independent of mutations in p53, RB and p16, known senescence mediators; instead, it is sustained through transcriptional suppression of SKP2, which degrades p27 and p21. Rare cells escaping senescence by restoring SKP2 expression display genomic instability. In > 200 cancer cell lines and in primary circulating tumor cells, SETD1A expression correlates with genes promoting mitosis and cell cycle suggesting a broad role in suppressing senescence induced by aberrant mitosis. Thus, SETD1A is essential to maintain mitosis and proliferation and its suppression unleashes the tumor suppressive effects of senescence.
S enescence is a prolonged state of growth arrest induced by a variety of stimuli including oncogene activation, oxidative and metabolic stress and mitotic aberrations 1, 2 . It is a physiological process involved in aging and age-related diseases 3, 4 and is an important tumor suppressor mechanism in premalignant tumors. A subset of these preneoplastic lesions including benign nevi, lung adenomas, and prostatic intraepithelial neoplasia eventually override this safeguard mechanism through the loss of p53, RB, INK4a and ARF and progress to malignant tumors [5] [6] [7] [8] . Senescence is also an alternative cellular response to chemo-and radiation-therapies, which induce extensive DNA damage. A minor fraction of therapy-induced senescent cells (TIS) override growth arrest through acquisition of stem-like properties 9 and unstable genomes 10 and the cells escaping senescence exhibit highly drug resistant phenotypes 11, 12 . However, the mechanisms that underlie senescence, particularly in cancer cells that have already inactivated RB and p53 signaling are not defined, and these may offer the potential for modulating this tumor suppressive pathway.
In a shRNA screen of chromatin modifiers 13 , we identified SETD1A as one of the most potent regulators of key genes driving mitosis. SETD1A encodes a highly conserved member of the multi-subunit Set1/COMPASS complex 14 , whose functional paralogues, Set1 and dSETD1 in yeast and Drosophila, respectively, are critical to maintain proliferation and viability [15] [16] [17] [18] [19] . Gene knockdown of Setd1a in mice causes severe proliferative defects during embryonic development 20 , suggesting that this function of SETD1A is evolutionarily conserved. Although the loss of SET proteins in multiple organisms causes extensive proliferative defects, their involvement in the maintenance of overall H3K4 methylation under these conditions has precluded our understanding of the specific molecular mechanisms underlying these functional defects.
Here we show that by regulating H3K4 methylation on the promoters of mitotic genes, SETD1A maintains the integrity of the mitotic process in cells. As a result, SETD1A knockdown, independent of the p53 and RB status in cells, leads to severe mitotic defects and senescence, suggesting that SETD1A plays a pivotal role in maintaining the balance between multiple cellular processes involved in cellular fitness.
Results
Suppression of SETD1A induces senescence. The overexpression of SETD1A in multiple tumor types 13 suggests an aberrant adaptation of this chromatin regulator in cancer cells. Analysis of publicly available data from 935 breast cancers (http:// www.cbioportal.org) shows that SETD1A is amplified in 7% of cases and in 12% of mixed ductal and lobular breast carcinomas (MDLC). Studies of clonal evolution in breast cancer patientderived xenografts in mice analyzed at single-cell resolution 21 show that 24% of the resulting tumors exhibit SETD1A gene amplification (Fig. 1a ). Furthermore, overexpression of SETD1A in breast cancers is associated with poor clinical outcome ( Fig. 1b ; Logrank P = 0.0035; HR = 5.03 (1. 51-16.8) ), suggesting that it confers a growth advantage in multiple tumor settings.
To study the role of SETD1A in cancer, we suppressed its expression in cancer cells. Remarkably, knockdown of SETD1A (SETD1A-KD) suppresses proliferation and triggers prompt (72 h) and massive cellular senescence, with very large cells expressing characteristic ß-galactosidase (ß-gal) activity ( Fig. 1c,  d ; Supplementary Fig. 1a , 1b, Data from three independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test). Suppressing SETD1A expression in the immortalized but non-tumorigenic human mammary epithelial cell line, MCF10A, also leads to increased senescence compared with shGFP expressing control cells ( Supplementary Fig. 1c , Data from two independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test). In addition to increasing the expression of the senescence core signature 22 ( Supplementary Fig 1d) , SETD1A-KD in cells increases cytokine and chemokine activity consistent with the senescence-associated secretory phenotype (SASP), both at the RNA and protein levels ( Fig. 1e, f) .
The cell cycle arrest resulting from SETD1A-KD (Supplementary Fig. 2a ; Data from three independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test) is consistent with cellular senescence, and it is not associated with apoptosis as seen by the absence of the caspase-3 and PARP cleavage markers of apoptosis, following 3and 7-days of SETD1A-KD 23, 24 (Fig. 2a ). Despite its developmental role in regulating global H3K4 methylation 20 , SETD1A-KD in cancer cells does not affect total H3K4 mono-, bi, or trimethylation, suggesting that the senescence phenotype in these cells is limited to more specific targets (Fig. 2b ). Induction of senescence following SETD1A-KD is observed in all cell lines tested (breast cancer, N = 4 cell lines; lung, N = 2 cell lines; colon, N = 7 cell lines), independent of the mutational status of TP53, RB, K-Ras and INK4A, known mediators of cellular senescence signals 1,2,25 ( Fig. 2c , Supplementary Fig. 2b ; Data from three independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test).
SETD1A induces mitosis and DNA damage response genes. To dissect the potential mechanisms underlying SETD1A-KD senescence, we performed transcriptome analysis using two different cell types (breast cancer MDA-MB-231 and lung cancer A549), in which SETD1A-KD induces senescence ( Fig. 1c, d , Supplementary Fig. 1b ). Comparison of the transcriptome changes in control and SETD1A-KD cells across both cell lines identified 345 shared transcripts that were suppressed by multiple shRNA constructs ( Supplementary Fig. 3a ). To determine which of these transcripts are directly regulated through SETD1Amediated changes in H3K4Me3 chromatin marks on their promoters, deposited through its methyl transferase activity 14 , we performed genome-wide H3K4Me3 ChIP-Sequencing in control and SETD1A-KD MDA-MB-231 cells. We identified 3258 loci with significant reduction in H3K4 trimethylation in cells, 42% of which resided within gene promoter regions ( Supplementary  Fig. 3b ). Overlapping the transcriptional and chromatin changes induced by shRNA suppression of SETD1A nominated 53 genes as candidate direct targets regulated by changes in H3K4Me3 chromatin marks on their promoters ( Fig. 3a , Supplementary  Fig. 3c ). As a third measure of functional significance, whole proteome analysis [(multiplexed mass spectrometry (MS)] using isobaric tandem mass tag (TMT) labeling 26, 27 of SETD1A-KD in both cell lines using two independent shRNA constructs, identified 33 of the 36 (92%) SETD1A targets detected by MS as being also reduced in protein expression ( Supplementary Fig. 3d ).
Gene Set Enrichment Analysis (GSEA) of the 53 consensus SETD1A targets identified pathways involved in mitosis and cell cycle regulation, and DNA-damage response as the top hits (FDR ≤ 0.25; Fig. 3a ). Consistent with these findings, in the Broad Institute genome-wide shRNA screening database across 285 cancer cell lines (www.broadinstitute.org/achilles), the top 10 pathways correlated with SETD1A-KD (accounting for 57% of genes analyzed), correspond to cell cycle and mitosis, of which 7 gene sets are significantly associated with sister chromatid cohesion ( Fig. 3b, Supplementary Fig. 4a ). SETD1A expression is similarly associated with mitosis, cell cycle and DNA damage response pathways, as demonstrated by high-throughput quantitative proteome data using 41 breast cancer cell lines 28 ( Fig. 3c, Supplementary Fig. 4b ). To define the extent to which the correlation between SETD1A expression and these cellular processes is relevant in clinical samples, we analyzed single-cell RNA-Sequencing data derived from primary patient-derived circulating tumor cells (CTCs) enriched from women with advanced breast cancer 29, 30 , which also confirmed the correlation in expression between SETD1A and genes involved in mitosis and DNA damage repair ( Fig. 3d ). Taken all together, these findings show that SETD1A expression, consistent with its methyl transferase activity, by modulating H3K4Me3 marks on promoters, positively regulates the expression of a subset of genes required for execution of cell division. These chromatin-mediated transcriptional effects resulting from the changes in SETD1Ainduced H3K4 methylation of promoters appear to differ from the role for SETD1A in mediating the survival of acute myeloid leukemia cells through a non-enzymatic function mediated through its interaction with cyclin K 31 .
SETD1A-KD induces mitotic defects. We then evaluated whether depletion of SETD1A in cells leads to mitotic defects. Dual tubulin and DAPI nuclear staining of SETD1A-KD cells shows a dramatic increase in the fraction of cells harboring micronuclei or chromosomal fragments ( Fig. 4a , bar graph shows data from three independent experiments presented as Mean + SD; IFNA14  IFNA16  IFNB1  IFNW1  IL10  IL12A  IL13  IL17C  IL19  IL1A  IL1RN  IL20  IL22  IL26  IL28B  IL29  IL32  IL6  IL8  IL9  INHA  INHBA  LEFTY1  LEFTY2   LTA  NODAL  SCGB3A1  SLURP1  SP100  TGFB2  TGFB3  THPO  TIMP1  TNF  TNFRSF11B  TNFSF11  TNFSF14  TNFSF15  TNFSF4  TNFSF8  TNFSF9  TSLP  XCL1  XCL2   CIB1  IL1RAP  HERC5  USP18  ISG20  SAMHD1  ISG15  MX2  STAT1  MX1  OASL  OAS1  OAS2  TRIM22 Real-time imaging of RFP-tagged H2B-expressing cells shows that mitotic defects precede the senescence phenotype exhibited by the SETD1A-KD cells (Supplementary movie 1, 2). Further analysis by co-staining with DAPI and antibodies against CREST, a protein marking the centromeres, also shows pronounced abnormalities in chromosome alignment during metaphase ( Fig. 4b , c, e, f; bar graphs show data from three independent experiments presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test). These are measured as metaphase plate abnormalities ( Fig. 4b , e; Arbitrary units; shGFP (n = 91 cells): 76 ± 17, shSETD1A av from constructs #1 and #2 (n = 91 cells): 98 ± 24; bar graph shows data from three independent experiments presented as Mean + SD; *p < 0.001 by two-tailed unpaired Student's t test) and as the fraction of cells with mis-aligned chromosomes ( Fig. 4c , f; shGFP (n = 47 cells): 24% ± 3%, shSETD1A av from constructs #1 and #2 (n = 89 cells): 41% ± 4%; bar graph shows data from three independent experiments presented as Mean + SD; *p < 0.001 by two-tailed unpaired Student's t test). Evaluation of anaphase cells demonstrates an increased fraction of cells with lagging chromosomes ( Fig. 4d , g; Mean + SD; shGFP (n = 43 cells): 24% ± 3%, shSETD1A av from constructs #1 and #2 (n = 68 cells): 53% ± 7%; bar graphs show data from three independent experiments presented as Mean + SD; *p < 0.01 by two-tailed unpaired Student's t test).
To expand on the observation that mitotic defects in proliferating SETD1A-KD cells are likely to be linked to the induction of the senescent phenotype, we took advantage of the tight dependence of MDA-MB-231 cell proliferation on glutamine supplementation in the culture medium, and their profound growth arrest following its withdrawal. Indeed, L-glutamine withdrawal from MDA-MB-231 cells, which suppresses proliferation ( Fig. 4h , Each data point represents data from three independent experiments presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test), mitigates the senescence phenotype observed following SETD1A-KD. Restoring Lglutamine to starved cells 24 hours after shSETD1A transfection triggers proliferation as well as the emergence of senescent cells (Fig. 4i , Data from three independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test). Thus, reduction of SETD1A expression in actively proliferating cells results in severe mitotic defects followed by cellular senescence.
SKP2 contributes to senescence in SETD1A-KD cells. Senescence-associated cell cycle arrest in SETD1A-KD cells, Gene dependencies correlated with SETD1A dependency (106 genes across 285 cell lines with FDR < 1%) CEP152  SASS6  TRAF3IP1  SNAP29  CEP78  HMMR  SKP2  LSM5  MYEOV2  DCLRE1C   ELP4  GEMIN6  ATAD2  SAP30  SETD1A  INTS2  TATDN1  RAD18  TSEN2  RAD50  BLM  BRCA2  XRCC2  FBXO5  STRA13  HELLS  KNTC1  BIRC5  CENPE  NUP37 Supplementary Fig. 3a ). shGFP-cells were used as control. Comparison of these 345 genes against 3258 H3K4 methylation marks suppressed in SETD1A-KD cells identified 53 direct SETD1A targets ( Supplementary Fig. 3a despite being independent of the mutational status of RB and p53 ( Fig. 2c, Supplementary Fig. 2b ), is associated with the induction of p21 and p27 (Fig. 5a ). The induction of p21 and p27 protein expression upon SETD1A-KD is also observed in the RB and p53 inactive MBA-MB-468 and BT549 cells ( Fig. 2c , Supplementary  Fig. 5 ). Having identified SKP2, the ubiquitin ligase which regulates the turnover of these two cell cycle regulators 32 , as a major direct target of SETD1A ( Supplementary Fig. 3c ), we tested whether SKP2 contributes to the induction of senescenceassociated cell cycle arrest in SETD1A-KD cells. Using qPCR and western blot analysis, we first confirmed that endogenous SKP2 mRNA and protein are indeed suppressed in MDA-MB-231 cells (Fig. 5b , Data from three independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test). and then used tiled ChIP-qPCR across the SKP2 transcriptional start site, identifying the suppression of H3K4Me3 marks in the proximity of the transcription start site (Fig. 5c , Data from three independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test).
To determine whether restoration of SKP2 expression in SETD1A-KD cells can rescue the senescence phenotype, we generated cells with 'doxycycline-inducible SKP2' expression ( Fig. 5d ). Inducible expression of SKP2 in SETD1A-KD cells (using two different shSET1A constructs) effectively reduced the expression of p27 and p21 proteins (Fig. 5d ). Staining for ß-Galactosidase shows that induction of SKP2 partially suppressed the emergence of ß-Gal-positive senescent cells by 50% following SETD1A-KD ( Fig. 5e , Data from three independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test).
Cells escaping senescence exhibit genomic instability. The link between SETD1A and SKP2 in mediating cellular senescence is further supported by the analysis of rare SETD1A-depleted cells that escape senescence after prolonged culture for over 90 days. The SETD1A-KD cells that escape senescence re-enter the cell cycle and resume proliferation and have reduced levels of ß-gal staining ( Fig. 6a-c ; Supplementary Fig. 6a , 6b, Data from three independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test). Since SETD1A-KD cells show extensive mitotic defects, we tested whether cells escaping senescence would exhibit genomic instability. Staining these cells with tubulin and DAPI demonstrated that these cycling cells harbor major chromosome segregation defects ( Fig. 6d , e, Data collected from 10 different fields per sample are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test). We confirmed that the escaping cells had initially suppressed SETD1A by performing single-cell cloning of control shGFP and SETD1A-KD cells and monitoring colony growth. Our results show that only 2 out of 190 (1.1%) SETD1A-KD cells gave rise to colonies compared with 89.4% in shGFP treated single cells ( Supplementary Fig. 6c ), suggesting that escape from senescence is a rare event in the model. qPCR analysis confirmed the continued presence of the shSETD1A construct within the cells escaping senescence ( Supplementary Fig. 6d ). In these senescence-escaping cells SETD1A expression remains only partially suppressed ( Supplementary Fig. 6e , Data from three independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test), and SKP2 mRNA expression is restored (Fig. 6f , Data from three independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test). To further determine whether recalibration of SETD1A and SKP2 expression in the SETD1A-KD senescent cells contributes to their escape, we knocked down their expression individually. In both instances, knockdown of either SETD1A or SKP2 re-induces the senescence phenotype ( Supplementary  Fig 6f, 6g) suggesting that the SETD1A-SKP2 axis maintains its important role in protecting cells from senescence. Unlike the SETD1A-KD senescent cells in which p27 expression is increased, the p27 protein levels in the senescence-escaping SETD1A-KD cells ( > 90 days) are similar to the control shGFP cells ( Supplementary Fig. 7 ). Taken together, these data indicate that rare cells may overcome SETD1A-KD-mediated senescence by reactivating SKP2 expression, partially through recalibrating SETD1A expression, but that they sustain persistent genomic instability, consistent with deregulation of the normal mitotic program.
Discussion
In summary, we report that knockdown of a single H3K4 methyltransferase, SETD1A, is sufficient to induce massive senescence in proliferating cells. We propose that this phenomenon stems from two convergent pathways: aberrant expression of genes critical for proper execution of mitosis, together with overexpression of the ubiquitin ligase SKP2, whose targets p21 and p27 are known mediators of cell cycle arrest as well as senescence 32 (Fig. 7) . These signals trigger senescence only in proliferating cells, given the absence of this phenotype in growth arrested cells. Taken together, these observations suggest that SETD1A plays a critical role in integrating the diverse components of cell division. Such a model would be consistent with SETD1A being required for embryonic, epiblast and neural stem cell survival 20 and the profound proliferative defects that accompany its loss in model organisms [15] [16] [17] [18] [19] .
Members of the COMPASS family are the most frequently mutated or rearranged chromatin regulators in many cancers 33 . Prevalence of mutations or translocations of SETD1A have not yet been reported cancer, however, SETD1A is amplified in mixed ductal and lobular and invasive breast carcinomas, suggesting that increased copy number might constitute one of the mechanisms responsible for its overexpression in cancer. Whether deregulation of DNA methylation could also elevate SETD1A expression in proliferating cancer cells remains to be determined. Cancer cells exhibit continued proliferation, often under conditions of mitotic stress and DNA damage. In this context, overexpression or even amplification of SETD1A may serve to confer enhanced fitness, allowing cells to tolerate some deregulation of mitotic pathways. In fact, amplification of the SETD1A gene in a high fraction (24%) of patient-derived breast cancer clones engrafting in mice could be attributed to the mitotic and cell cycle competence acquired by these high SETD1A expressing tumor cells 21 .
Although senescence-associated cell cycle arrest is mostly irreversible, a minor fraction of cells does escape senescence and these cells often exhibit more aggressive phenotypes 12, 34 . Identifying mechanisms that promote the escape from senescence and re-entry of cells into the cell cycle is critical to maximally exploit the tumor suppressive properties of senescence. Progression of premalignant lesions into malignant tumors predominantly occurs through the loss of p53, INK4a and ARF 35 , whereas mechanisms enabling therapy-induced senescent cells to escape cell cycle arrest are highly context dependent and include the activation of CDK1/cdc2 36 , maintenance of stem cells through ATR and/or Wnt-dependent 37,38 pathways as well as activation of survival mechanisms 39 . In the SETD1A-KD senescence model, we identify restoration of SKP2 as one of the mechanisms that facilitates the escape of a rare population of mitotically defective cells. Recalibration of SETD1A expression may contribute to restoration of SKP2 expression in the senescence-escaping cells, since repeat knockdown either SETD1A or SKP2 can re-establish the senescence phenotype. We had previously shown that SETD1A, through the induction of a network of miRNAs, suppresses the expression of several p53 downstream targets including BTG2 13 , an inhibitor of cell cycle progression 40 . Knockdown of BTG2 in SETD1A-KD cells also decreases the fraction of ß-gal positive cells implicating additional mechanisms in the escape of SETD1A-KD cells from senescence (Supplementary Fig. 8 , Data from three independent experiments are presented as Mean + SD; *p < 0.05 by two-tailed unpaired Student's t test)
Senescence is not only a potent tumor-suppressive and drugresponse mechanism, it is also thought to be a fundamental cellular pathway that drives organismal aging 3, 4 . As such, SETD1A, a chromatin modifying enzyme which integrates two fundamentally opposing pathwaysproliferation and senescenceprovides a druggable node that may provide insight into modulating cancer and aging phenotypes in the future. Histone-modifying enzymes, which regulate transcriptional programs, are emerging as promising cancer therapeutic targets [41] [42] [43] . Our findings show that inhibiting SETD1A is sufficient to unleash the senescence phenotype illustrating the potential consequence of targeting a single chromatin modifier. For cancer applications, exploiting the senescence phenotype induced by SETD1A inhibition will require identifying additional actionable signaling nodes to suppress escape from senescence, and combinatorial regimens to definitively halt cancer cell proliferation.
Methods
Cell culture. All cell lines were acquired from ATCC. Human breast and lung cancer cell lines, MDA-MB231, A549, MCF7, MDA-MB-468, BT549, and H1299, were grown in Dulbeccco's modified medium supplemented with 10% female fetal bovine serum, glutamine and penicillin/streptomycin. Human colon cancer cell lines, HCT8, H630, HCT116, DLD1, HCT15, SW620 and HT29, were grown in RPMI 1640 medium supplemented with 10% female fetal bovine serum and penicillin/streptomycin. They were periodically authenticated and were matched with the earliest passage cell lines. All cell lines were also periodically tested for mycoplasma contamination using the MycoFluorTM Mycoplasma Detection Kit (Thermo Fisher Scientific) and shown as negative for infection. Table 1 . Inducible expression of SKP2 was accomplished by stable lentiviral transfection of pInducer-SKP2 into cells. The sequence pENTR-SKP2, Ultimate ORF from Life Technologies, was transferred to the backbone pInducer 20 with the gateway system from Life Technologies. Conditioned medium containing infective lentiviral particles was generated by cotransfecting 3 µg of lentiviral vector, 3 µg of pCMV ∂8.91 and 1 µg pHCMV-VSV-G into 2 × 10 6 293 T human embryonic kidney cells using FuGENE 6 transfection reagent (Roche Applied Science). Supernatants were collected 48 hours after transfection and filtered through a 0.45 um membrane (Millipore). The cells were directly infected using 8 µg/mL of polybrene.
RNA interference assay. siRNA against BTG2 (5′-CAGAGCACUACAAA-CACCACUGGUU-3′) or non-targeting control (50 nM) were transfected into cells using the Lipofectamine RNAiMAX (Invitrogen) according to manufacturer's protocol.
qPCR. RNA was isolated using RNeasy Mini kit (Qiagen) and mRNA quantitation was performed using SYBR Green in an ABI PRISM 7500 sequence detection system with 96-block module and automation accessory (Applied Bio-system). GAPDH or ß-actin was used as an internal control. All samples were analyzed in triplicate. The primer sequences are listed in the Table 2 .
Western blot. Antibodies used were rabbit anti-SETD1A polyclonal antibody (Cat. A300-289 A, BETHYL; 1:1000 dilution), rabbit anti-p21 polyclonal antibody (Cat. sc-397, Santa Cruz; 1:100 dilution), rabbit anti-p27 polyclonal antibody (Cat. sc-528, Santa Cruz; 1:100 dilution), rabbit anti-caspase-3 polyclonal antibody (Cat. sc-7148; 1:200 dilution), rabbit anti-PARP antibody (Cat. #9542; Cell Signaling Technology; 1:1000 dilution), rabbit anti-Histone H3 antibody (Cat. ab176842, Abcam; 1:500 dilution), rabbit anti-SKP2 antibody (Cat. #4358; Cell Signaling), rabbit anti-Histone H3 mono-methyl K4 antibody (Cat. ab8895; Abcam; 1:500 dilution), rabbit anti-Histone H3 di-methyl K4 antibody (Cat. ab32356; Abcam; 1:2000 dilution), rabbit anti-Histone H3 tri-methyl K4 antibody (Cat. ab12209; Abcam; 1:1000 dilution) and mouse anti-Actin monoclonal antibody (BD Bioscience; 1:1000 dilution Table 2 The primer sequences used for gene expression analysis using qPCR
Cell cycle analysis. Cells were harvested, washed twice in PBS, resuspended in 70% ethanol overnight, and then diluted in propidium iodide, RNase staining buffer (BD Pharmingen) and incubated for 15 min at 37°C. Samples were analyzed with flow cytometry (BD LSRFortessa Cell analyzer) and Flowjo software (FLOWJO, LLC).
Time-lapse imaging. H2B-RFP-expressing A549 cells were infected with either shSETD1A or shGFP and real-time imaging was initiated 24 hours after infection using the confocal Zeiss LSM170 using an enclosed stage incubator, after regulating temperature, CO 2 level and humidity. For RFP images within each well, nine images (3 × 3 tile) were captured every 5-8 min over 3 days (24-96 h after infection) at ×20 magnification. Sample focus was maintained during the course of the experiment using an external diode laser. Cell viability was confirmed by observing of mitotic cells throughout the duration of the experiment. Videos were analyzed using the ZEN software (Zeiss).
Proliferation assays. Cells were trypsinized and 2.5 × 10 3 cells were plated in individual wells of a 96-well plate. On the day of evaluation, a 10 µL WST-8 solution (WST-8 cell proliferation and cytotoxicity assay kit; Cayman Chemical) was added into each well. Plates were then incubated for an additional 1 h at 37°C and the absorbance was determined at 450 nm. The cell counts for 3 wells/timepoint were averaged for each group and the data were used to derive growth curves.
ChIP-Sequencing. ChIP assay to define H3K4Me3 marks on the SKP2 promoter using 10 primers spanning the region was done as described in 13 . Quantitative PCR was performed using primers listed in the Table 3 . Distribution of global histone H3 harboring H3K4me3 marks in shGFP and SETD1A-KD cells (from three independent samples) was determined by ChIPseq 44 . Cells at 80% confluence in 150 mm dishes (3 × 10 6 -5 × 10 6 cells per dish) were crosslinked with 1% formaldehyde for 15 min at 37°C and quenched with formaldehyde containing 125 mM glycine. The cells were then washed twice with cold PBS and collected into 1 mL of cellular lysis buffer (5 mM Pipes, 85 mM KCl, and 0.5% NP-40 with protease inhibitors mixture). Nuclei were collected and incubated in nuclear lysis buffer [50 mM Tris (pH 8.0), 10 mM EDTA (pH 8.0), 0.2% EDTA with protease inhibitors mixture]. Formaldehyde-crosslinked chromatin was fragmented to a target size of 200-300 bp using a Covaris S2 sonicator (Covaris, Woburn, MA) at 4°C. Size distribution of gDNA fragments was determined using the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA). Protein G magnetic beads were incubated with 4 µg of either anti-Histone H3 tri-methyl K4 antibody or IgG control on rotator at 4°C for 6 h. Sonicated chromatin was subjected to chromatin immunoprecipitation with protein G magnetic beads conjugated with each antibody on rotator at 4°C overnight. After six washes, the beads were eluted with elution buffer (50 mM NaHCO 3 , 140 mM NaCl, 1% SDS). Following both RNaseA and proteinase K treatment, genomic DNA fragments enriched for interaction with H3K4me3 were released from proteins by heat, purified using PCR clean-up kit (Qiagen), and subjected to deep sequencing library construction using the SOLiD 5500 Fragment Library Core Kit and the SOLiD EZ Bead emulsion PCR system (Life Technologies, Carlsbad, CA). Deep sequencing was performed using the SOLiD 5500XL deep sequencer (50 nt, single reads), and the XSQ-format raw data were subjected to color-space alignment to the GRCh37/hg19 human genome reference sequence to obtain the BAM format-aligned read data using the ABI LifeScope software (Life Technologies). Uniquely mapped reads (12-15 million reads per library) were subjected to detection of H3K4me3 peaks and differential distributions using the MACS2 callpeak function 45 . Annotation of H3K4me3 peaks to the transcription start sites of known human genes was performed using the R/bioconductor packages ChIPseeker 46 , clusterProfiler 47 , and TxDb.Hsapiens.UCSC.hg19. knownGenes. Gene Ontology analysis of genes differentially enriched for H3K4me3 at the promoter sequence was performed using the DAVID web server 48 . Quantitative differences in promoter-associated H3K4me3 peaks within known genes were statistically examined using two-samples t test with Welch's correction. ChIP sequencing data have been deposited in the NCBI Gene Expression Omnibus database under accession code GSE 117427.
Arrayed gene expression analysis. RNA expression in SETD1A-depleted A549 and MDA-MB-231 cells was analyzed using the Human Gene Expression 12 × 135 K Arrays (Roche Nimblegen). Briefly RNA was extracted from A549 and MDA-MB-231 cells infected with shGFP or two independent shSETD1A constructs (shSETD1A#1 and shSETD1A#2) using the RNeasy Mini kit (Qiagen). cDNA synthesis was performed using the Roche cDNA synthesis system (11 117 831 001). cDNA was hybridized to the Human Gene Expression 12 × 135 K Arrays in duplicate according to the manufacturer's protocol. The microarrays were scanned on Nimblegen MS200 at 2 µm resolution. Scans were converted to RMAnormalized 49, 50 expression values using Roche NimbleScan 2.6 software. Microarray data have been deposited in the NCBI Gene Expression Omnibus database under accession code GSE 71498 13 .
Quantitative proteomics. To define the mechanism underlying the senescence phenotype exhibited by SETD1A knockdown cells, we quantitatively mapped the proteomes using multiplexed mass spectrometry (MS) by applying isobaric tandem mass tag (TMT) technology 26, 27 . shGFP and shSETD1A MDA-MB-231 and A549 cells (carried out in triplicate) were pelleted and re-suspended in lysis buffer containing 75 mM NaCl, 50 mM HEPES (pH 8.5), 10 mM sodium pyrophosphate, 10 mM NaF, 10 mM ß-glycerophosphate, 10 mM sodium orthovanadate, 10 mM phenylmethanesulfonylfluoride, Roche Complete Protease Inhibitor EDTA-free tablets, and 3% sodium dodecyl sulfate. Cells were lysed by passing them 10 times through a 21-gauge needle, and the lysates were prepared for analysis on the mass spectrometer 28 . Briefly, reduction and thiol alkylation were followed by purifying the proteins using MeOH/CHCl3 precipitation. Protein digest was performed with Lys-C and trypsin, and peptides were labeled with TMT-10-plex reagents (Thermo Scientific) and fractionated by basic pH reversed phase chromatography. Multiplexed quantitative proteomics was performed on an Orbitrap Fusion mass spectrometer (Thermo Scientific) using a Simultaneous Precursor Selection (SPS) based MS3 method 26, 27 . MS2 spectra were assigned using a SEQUEST-based proteomics analysis platform 51 . Based on the target-decoy database search strategy 52 and employing linear discriminant analysis and posterior error histogram sorting, peptide and protein assignments were filtered to a false discovery rate (FDR) of <1% 53 . Peptides with sequences that were contained in more than one protein sequence from the UniProt database were assigned to the protein with most matching peptides 53 . TMT reporter ion intensities were extracted as that of the most intense ion within a 0.03 Th window around the predicted reporter ion intensities in the collected MS3 spectra. Only MS3 with an average signal-to-noise value larger than 40 per reporter ion as well as with an isolation specificity 27 larger than 0.75 were considered for quantification. A two-step normalization of the protein TMT-intensities was performed by first normalizing the protein intensities over all acquired TMT channels for each protein based on the median average protein intensity calculated for all proteins. To correct for slight mixing errors of the peptide mixture from each sample, a median of the normalized intensities was calculated from all protein intensities in each TMT channel, and protein intensities were normalized to the median value of these median intensities. Known proteinprotein interactions were extracted from the String database (high confidence score > 0.7) 54 .
Analysis of gene sets enriched in SETD1A co-regulated genes. Data derived from multiplexed proteomic analysis on 41 breast cancer cell lines described in ref. 28 were used to calculate the co-regulation of all proteins with respect to endogenous basal SETD1A protein expression using pairwise Pearson correlation calculations 28 . The correlation scores were sorted to generate an ordered list of proteins and then the proteins identifiers were converted to their associated gene symbol. We performed a GSEA for the GO term Biological Process gene set collection (MSigDB) using the pre-Ranked GSEA tool available from the Broad 55 . Significantly enriched genesets were defined by the Benjamini-Hochberg adjusted p values (FDR q values < 25%). The full set of significantly enriched gene sets are provided as Supplementary table 1. SETD1A co-dependency analysis. The Project Achilles RNAi viability database was analyzed to identify the gene dependencies that are most closely associated with SETD1A dependency. This analysis was performed on the published Achilles v2.20.2 dataset, comprised of 17,098 gene dependency z-score across 501 cancer NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10786-w ARTICLE cell lines; however, since SETD1A dependency was only measured in a subset of 285 cell lines, only this subset was analyzed 56 . Gene dependencies were ranked by Pearson correlation coefficient with SETD1A dependency across 285 lines, and false discovery rate (FDR) was controlled by the Benjamini and Hochberg method. The overlap of positively correlated gene dependencies (FDR < 0.01) with GO gene sets was evaluated using Gene Set Enrichment Analysis (GSEA, MSigDB v6.1, c5 gene sets) 55, 57 . For gene dependencies represented in multiple enriched and related GO gene sets, a heatmap was generated to depict the association with SETD1A dependency, comparing the gene dependency z-scores in cell lines that are SETD1A-dependent (z-score < -2) and SETD1A-independent (z-score > + 2).
Immunofluorescence analysis. Cells were plated overnight on a 4 or 8-well chamber slide (Millipore or LAB-TEK) coated with poly-L-lysine (Sigma), fixed with 4% paraformaldehyde and washed with PBS. Fixed cells were then permeabilized with 0.5% Triton X-100 in PBS, blocked with 5% BSA, and stained with mouse anti-Tubulin antibody (NOVUS; 1:200 dilution) or human anti-Centromere antibody (Antibody Inc; 1:200 dilution) for 1 h, and incubated with secondary antibodies conjugated with Alexa Fluor dyes (1:500 dilution) for 1 h. Coverslips were then mounted with anti-fade agent Prolong with 4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen). Photomicrographs were taken with the NIKON 90i microscope or with the confocal Zeiss LSM170. Analysis and quantification of the mitotic events of interest were performed with ImageJ software (NIH).
Statistics. The statistical analyses performed is described in the figure legends. The differences between the means were considered to be statistically significant at P < 0.05.
Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Microarray data has been deposited in the NCBI Gene Expression Omnibus database under accession code GSE71498. The proteomics data have been deposited to the ProteomeXchange Consortium via the MassIVE partner repository with the dataset identifier MSV000083763. The source data underlying Figs. 1a, 1c, d, 2a -c, 3d, 4a-i, 5a-e, 6a, 6c-g and Supplementary Figs. 1a-d, 2a , 3c, 5, 6a-c, 6e-gd, 7 and 8 are provided as a Source Data file. All the other data supporting the findings of this study are available within the article and its Supplementary Information files and from the corresponding author upon reasonable request.
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